Last Update 15 Apr 26

TWST: Bispecific Platform Deal And Tools Recovery Will Shape Multi Year Outlook

Twist Bioscience's updated analyst price target remains at $58.00. Recent Street research cites revised assumptions around revenue growth, profitability, and a lower future P/E as key drivers behind the refreshed narrative.

Analyst Commentary

Recent Street research around Twist Bioscience centers on a series of upward price target revisions, with bullish analysts revisiting their models and assumptions on revenue trajectories, profitability, and future P/E levels. The latest updates cluster over a relatively short period, which keeps attention on how the company executes against current expectations.

Several firms have published higher price targets in recent months, including multiple revisions in close succession from the same institutions. Taken together, these moves reflect a period where analysts are reassessing what they see as the potential upside case for the stock, even as views on valuation and risk can differ across the Street.

Bullish Takeaways

Multiple bullish analysts have raised price targets by mid to high single digit dollar amounts, signaling greater conviction in the company’s potential to support a higher valuation over time.
Some firms have issued larger, double digit price target revisions, which points to a more constructive stance on the company’s execution and long term growth opportunity.
The clustering of upward target moves in a relatively tight time frame suggests that several research teams are updating models at the same time, keeping positive sentiment around the name in focus for institutional clients.
Repeated target adjustments from the same institutions indicate that bullish analysts are revisiting their assumptions, including revenue build, path to profitability, and acceptable future P/E levels, rather than relying on static views.

What's in the News

Twist Bioscience entered a licensing agreement with Invenra Inc., becoming a co-exclusive provider of Invenra's B-Body bispecific antibody platform and extending Twist's antibody discovery services across in vivo, in vitro and AI-enabled methods (Key Developments).
Under the Invenra agreement, Twist will pay an upfront US$5 million in cash and US$15 million in Twist common stock, and in a separate transaction is taking an approximately 6% ownership stake in Invenra through a US$13.8 million preferred stock purchase from existing Invenra shareholders (Key Developments).
Twist receives all revenue from bispecific antibody discovery services conducted by Twist and all license revenue related to the platform, while paying Invenra a 20% royalty on license revenue (Key Developments).
The company launched the Twist TrueAmp Library Preparation Kit and the Twist PCR-Free WGS Library Preparation Kit, aimed at handling low input and challenging samples for clinical research and whole genome sequencing, with a focus on coverage of hard to sequence regions and high quality data output (Key Developments).
Twist issued fiscal 2026 guidance, expecting total revenue of US$435 million to US$440 million, and for the second quarter of fiscal 2026 expects total revenue of US$107 million to US$108 million, with the company indicating approximately 16% year over year growth at the midpoints and a revenue mix that is generally balanced across DSPS and NGS (Key Developments).

Valuation Changes

Fair Value: $58.00 remains unchanged in the updated work. This signals no shift in the headline valuation anchor.
Discount Rate: The discount rate has risen slightly from 7.12% to 7.16%, implying a marginally higher required return in the model.
Revenue Growth: The revenue growth assumption has risen slightly from 17.20% to 17.61%, indicating a modestly higher top line outlook in the latest assumptions.
Net Profit Margin: The net profit margin assumption has risen significantly from 1.90% to 14.75%, reflecting a much higher modeled profitability level over time.
Future P/E: The future P/E multiple has fallen significantly from 386.39x to 49.36x, pointing to a far lower valuation multiple applied to earnings in the updated analysis.

0 views

Key Takeaways

Twist's margin expansion and rapid product innovation are driving accelerating profitability and positioning the company for industry-leading financial performance.
Expanding demand for synthetic biology, AI-driven drug discovery, and disruptive new markets sets the stage for resilient, compounding revenue and substantial long-term upside.
Sustained pricing pressure, persistent unprofitability risk, execution challenges in new markets, volatile funding, and heightened regulatory or supply chain risks all threaten future profitability.

Catalysts

About Twist Bioscience

Manufactures and sells synthetic DNA-based products.What are the underlying business or industry changes driving this perspective?

While analyst consensus expects process improvements and product mix to lift gross margins moderately, the company's relentless execution has already delivered a leap from 31% to above 53% in just two years, with ongoing vertical integration and rapid product cycles positioning Twist to achieve industry-leading margins far above current forecasts-potentially transforming EBITDA and net income even faster than expected.
Analysts broadly agree that Twist's best-in-class automated synthesis and strong commercial execution will drive robust revenue growth, yet this view may be conservative: the accelerating pace of customer wins, rapid new product rollouts, and expanding reach into "long tail" academic and industrial accounts is setting the stage for compounding, double-digit revenue expansion and highly resilient recurring revenue, especially as the company converts smaller accounts into scaled, sticky customers.
Growing global adoption of synthetic biology and a paradigm shift towards precision/personalized medicine is dramatically expanding the need for high-quality, scalable DNA synthesis; as industry leader, Twist is uniquely positioned to supply these critical inputs, enabling exponential growth in its addressable market and fueling long-term top-line acceleration.
Intensifying adoption of AI-driven drug discovery, coupled with swelling investment in next-gen biomanufacturing, is unleashing new high-value use cases for customized DNA and antibody libraries, making Twist the partner of choice for large pharma and synthetic bio innovators-driving not only higher ASPs but recurring multi-year contracts that can structurally increase revenue and margin visibility.
Strategic investments in disruptive areas like DNA-based data storage, enabled by proprietary platform advances, are nearing commercial inflection; as these initiatives transition from R&D to revenue, Twist has the potential to open entirely new multi-billion-dollar markets, providing massive long-term upside and supporting both rapid revenue growth and superior earnings leverage.

Twist Bioscience Earnings and Revenue Growth

Twist Bioscience Future Earnings and Revenue Growth

Assumptions

How have these above catalysts been quantified?

This narrative explores a more optimistic perspective on Twist Bioscience compared to the consensus, based on a Fair Value that aligns with the bullish cohort of analysts.
The bullish analysts are assuming Twist Bioscience's revenue will grow by 17.6% annually over the next 3 years.
The bullish analysts are not forecasting that Twist Bioscience will become profitable in next 3 years. To represent the Analyst Price Target as a Future PE Valuation we will estimate Twist Bioscience's profit margin will increase from -19.6% to the average US Biotechs industry of 14.8% in 3 years.
If Twist Bioscience's profit margin were to converge on the industry average, you could expect earnings to reach $94.0 million (and earnings per share of $1.43) by about April 2029, up from -$76.6 million today.
In order for the above numbers to justify the price target of the more bullish analyst cohort, the company would need to trade at a PE ratio of 49.9x on those 2029 earnings, up from -46.0x today. This future PE is greater than the current PE for the US Biotechs industry at 17.7x.
The bullish analysts expect the number of shares outstanding to grow by 2.33% per year for the next 3 years.
To value all of this in today's terms, we will use a discount rate of 7.16%, as per the Simply Wall St company report.

Risks

What could happen that would invalidate this narrative?

Accelerating commoditization and intense competition in the synthetic DNA and NGS (Next-Generation Sequencing) markets may put sustained pricing pressure on Twist Bioscience's products, risking future erosion of gross margin and overall profitability.
Ongoing negative operating margins and a projected adjusted EBITDA loss, despite improved gross margins, highlight the persistent risk that Twist Bioscience may remain unprofitable for an extended period, threatening future earnings and shareholder value if revenue growth slows or cost discipline falters.
A reliance on continued rapid customer adoption for new and innovative products, especially in nascent markets like MRD (Minimal Residual Disease) and AI-driven drug discovery, introduces execution risk that could result in revenue shortfalls if uptake is slower than anticipated or competitors commercialize similar technologies more effectively.
U.S. academic and industrial chemical funding environments remain uncertain and somewhat volatile, which, when coupled with broader macroeconomic trends such as rising interest rates and tighter credit, could constrain spending from key customers and reduce revenue predictability.
Heightened geopolitical and regulatory risks, including the possibility of stricter bioethics regulations, evolving trade barriers, or supply chain disruptions for key reagents and components, could increase operational costs or delay production, potentially impacting both revenue and net income over the long term.

Valuation

How have all the factors above been brought together to estimate a fair value?

The assumed bullish price target for Twist Bioscience is $58.0, which represents up to two standard deviations above the consensus price target of $51.44. This valuation is based on what can be assumed as the expectations of Twist Bioscience's future earnings growth, profit margins and other risk factors from analysts on the bullish end of the spectrum.
However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of $58.0, and the most bearish reporting a price target of just $36.0.
In order for you to agree with the more bullish analyst cohort, you'd need to believe that by 2029, revenues will be $637.1 million, earnings will come to $94.0 million, and it would be trading on a PE ratio of 49.9x, assuming you use a discount rate of 7.2%.
Given the current share price of $57.41, the analyst price target of $58.0 is 1.0% higher. The relatively low difference between the current share price and the analyst consensus price target indicates that they believe on average, the company is fairly priced.
We always encourage you to reach your own conclusions though. So sense check these analyst numbers against your own assumptions and expectations based on your understanding of the business and what you believe is probable.

Have other thoughts on Twist Bioscience?

Create your own narrative on this stock, and estimate its Fair Value using our Valuator tool.

Create Narrative

How well do narratives help inform your perspective?

Disclaimer

AnalystHighTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystHighTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystHighTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.

Automated DNA Synthesis And AI Will Fuel Secular Growth